Équipe de Yannick ARLOT

Bases moléculaires de la tumorigenèse : maladie de VHL

Yannick ARLOT

Responsable d'équipe

> Mail: yannick.arlot@univ-rennes1.fr

> Tel: + 33 2 23 23 46 96

 

Publications majeures

Publications majeures

  •  New lessons from an old gene: complex splicing and a novel cryptic-exon in VHL gene cause erythrocytosis and Von Hippel Lindau disease
     Lenglet M., Robriquet F., Schwarz K., Carme C., Couturier A., Hoogewijs D., Buffet A ., Knight S., Gad S., Couvé .S., Chesnel F., Pacault M., Lindenbaum P., Job S., Dumont S., Besnard T., Cornec M., Deveaux S., Burnichon N., Ferlicot S., Vilaine M., Mazzella JM., Airaud F., Garrec C., Heidet L., Irtan S., Mantadakis E., Bouchireb K., Debatin KM., Redon R., Bezieau S., Bressac-de Paillerets B., Teh Bin T., Girodon F., Randi ML., Putti MC., Bours V., Van Wijk R., Göthert J., Kattamis A., Janin N., Bento C., Taylor JC., Arlot-Bonnemains Y., Richard S., Gimenez-Roqueplo AP., Cario H., Gardie B. . 
     2018 Jun 11.  doi: 10.1182/blood-2018-03-838235

    The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13
    P Hascoet ,  F Chesnel, F Jouan , C Le Goff , A Couturier, E Darrigrand , F Mahé , N Rioux-Leclercq ,  X Le Goff , Y Arlot-Bonnemains  
    Oncotarget - 2017 June

    Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer.
    Tuccilli C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, D'Armiento E, Antonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S, Mian C, Arcieri S, Mascagni D, Pironi D, Bononi M, Vergine M, Monti M, Filippini A, Ulisse S.
    ​Int J Oncol. 2017 Mar 

    Deregulated expression of VHL mRNA variants in papillary thyroid cancer
    Baldini E, ,Tucilli C Arlot-Bonnemains  Y Chesnel, F, Sorrenti S, De Vito C, Catania A, D’Arminento e, Entonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S Mian C, Bononi M, Arceri,S, Mascagni D, Vergine M, Pironi D, Monti M, Fillipini A, Ulisse SW
    Mol.Cell. Endocrinol. 2017 Mar  

    SHIP2 regulates lumen generation, cell division and ciliogenesis through the control of basolateral to apical lumen localization of Aurora A and HEF 1
    O Hamze Komaiha, S Sarr Y Arlot-Bonnemains , DSamuel, and A Gassama-Diagne 1
    Cell Reports  2016 Dec   

    Aggregation dynamics and identification of aggregation-prone mutants of the von Hippel Lindau tumor suppressor protein
    Le Goff X, Chesnel, F, Delalande O, Couturier A, Dreano S, Le Goff C, Vigneau C, Arlot-Bonnemains Y
    ​J Cell Science 2016 Mai   

    Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis 
    Hascoet P, Chesnel F, Le Goff C, Le Goff X, Arlot-Bonnemains Y.
    Front Oncol. 2015 Oct 

    The Von Hippel Lindau tumor suppressor gene: Uncovering the expression of the pVHL172
    Chesnel F, Hascoet P, GagneJP, Couturier A,  Jouan F, Poirier G, Le Goff C, Vigneau C, Danger Y, Verite F , Le Goff X, & Arlot-Bonnemains Y.
    Br J Cancer. 2015 Jun.

    Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis
    Dugay F, Le Goff X, Rioux-Leclerq N, Chesnel F, Jouan F, Henry C, Cabillic F, Verhoest G, Vigneau C, Belaud-Rotureau MA and Arlot-Bonnemains Y. (YAB And MABR are co-last authors YAB is the correpsonding  author)
    Int J Cancer. 2014 May 

    Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma  (ccRCC)
    Martin B, Chesnel F, Delcros JG, Jouan F, Couturier A, Dugay F, Le Goff X, Patard JJ, Fergelot P, Vigneau C, Rioux-Leclerq N, Arlot-Bonnemains Y
    PLoS One. 2013 Jun

  • Etude des fonctions des isoformes de pVHL dans la progression tumorale

Souscrire à notre Newsletter